Eisai: latest news - GoINPHARMA
Sunday, 24 March 2019 - 18:35


Japanese generics market consolidates

Japan-based pharmaceutical groups Nichi-Iko Pharmaceutical and Eisai have announced a strategic partnership in the generics business. As part of the agreement, Eisai will sell its subsidiary Elmed Eisai–manufacturing generics–to Nichi Iko for €130m (JY17.12bn). As part of the agreement, the…

Merck & Co. signs multi-billion agreement with Eisai on Keytruda

US-based pharmaceutical group Merck & Co has entered into an agreement with Japan-based  Eisai Co aimed at further developing and, subsequently, marketing cancer drug Lenvima (lenvatinib), a treatment discovered by Eisai which has already been approved for a dozen cancer…

New terms for Biogen/Eisai agreement

Eisai Co. and Biogen Inc. have announced they have extended their already existing collaboration agreement to develop and market new Alzheimer’s treatments. Under the terms of the agreement, Eisai has exercised its option to jointly develop and commercialize aducanumab, Biogen’s…

FDA grants fast track for Eisai/Biogen’s BACE inhibitor

Eisai announced today that its product E2609, BACE (Beta-secretase Cleaving Enzyme) inhibitor, has received Fast Track designation. The product is currently in Phase III development, specifically in clinical trials designed in order to assess its efficacy for early Alzheimer’s disease….